Tremor and ataxia in fragile X premutation carriers: Blinded videotape study

Annals of Neurology

Volumn 53, Issue 5, 2003, Pages 616-623

  Berry Kravis, Elizabeth ^a   Lewin, Foster ^a   Wuu, Joanne ^a   Leehey, Maureen ^b   Hagerman, Randi ^c   Hagerman, Paul ^c   Goetz, Christopher G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; GUANINE;

ADULT; AGED; ARTICLE; ATAXIA; BODY POSTURE; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FRAGILE X SYNDROME; GAIT DISORDER; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HETEROZYGOTE; HUMAN; MALE; NUCLEOTIDE REPEAT; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; SINGLE BLIND PROCEDURE; SYMPTOM; TREMOR; VIDEOTAPE;

AGED; ATAXIA; ATROPHY; CENTRAL NERVOUS SYSTEM; DNA MUTATIONAL ANALYSIS; FEMALE; FRAGILE X SYNDROME; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; RNA, MESSENGER; TREMOR; VIDEOTAPE RECORDING;

EID: 0038754166     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10522     Document Type: Article

References (31)

1. Verkerk AJMH, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat co-incident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-914.
2. Pieretti M, Zhang F, Fu Y-H, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991;66:817-822.
3. Devys D, Lutz Y, Rouyer N, et al. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet 1993;4:335-340.
4. Fu Y-H, Kohl DPA, Pizzuit A, et al. Variation of the CGG repeat at the fragile X site results in genetic instability and resolution of the Sherman paradox. Cell 1991;67:1047-1058.
5. Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation-size alleles of the FMR1 gene, and implications for the population genetics of the fragile X syndrome. Am J Hum Genet 1995;57:1006-1018.
6. Dombrowski C, Levesque S, Morel ML, et al. Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 2002;11:371-378.
7. Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Cronister A, eds. Fragile X syndrome: diagnosis, treatment and research. Baltimore: Johns Hopkins University Press, 1996:3-87.
8. Franke P, Leboyer M, Hardt J, et al. Neuropsychological profiles of FMR-1 premutation and full-mutation carrier females. Psychiatry Res 1999;87:223-231.
9. Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000;91:144-152.
10. Hagerman RJ, Staley LW, O'Connor R, et al. Learning disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics 1996;97:122-126.
11. Franke P, Maier W, Hautzinger M, et al. Fragile X carrier females: evidence for a distinct psychopathological phenotype. Am J Med Genet 1996;64:334-339.
12. Dorn MB, Mazzocco MMM, Hagerman RJ. Behavioral and psychiatric disorders in adult male carriers of fragile X. J Am Acad Child Adolesc Psychiatry 1994;33:256-264.
13. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000;97:189-194.
14. Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in fragile X syndrome. Am J Hum Genet 2000;66:6-15.
15. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001;57:127-130.
16. Fahn S, Tolosa E, Marin C. Clinical Rating Scale for Tremor. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore, Munich: Urban and Schwarzenberg, 1998:225-234.
17. Trouillas P, Takayanagi T, Hallet M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci 1997;45:205-211.
18. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Godstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Health Care Information, 1987:153-164.
19. Goetz CG, Stebbins GT, Chmura TA, et al. Teaching tape for the motor section of the Unified Parkinson's Disease Rating Scale videotape accompanies text. Mov Disord 1995;10:263-266.
20. Tison F, Yekhlef F, Chrysostome V, et al. Parkinsonism in multiple system atrophy: natural history, severity (UODRS-III), and disability assessment compared with Parkinson's disease. Mov Disord 2002;17:701-709.
21. Levinson G, Maddalena A, Palmer FT, et al. Improved sizing of fragile X CCG repeats by nested polymerase chain reaction. Am J Med Genet 1994;51:527-534.
22. Rousseau F, Heitz D, Biancalana V, et al. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Engl J Med 1991;325:1673-1681.
23. Stebbins GT, Goetz CG. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination Section. Mov Disord 1998;13:633-636.
24. Stebbins GT, Goetz CG, Lang AE, Cubo E. Factor analysis of the motor section of the Unified Parkinson's Disease Rating Scale during the off-state. Mov Disord 1999;13:585-589.
25. Leehey M, Hagerman RJ, Landau WM, et al. Tremor/ataxia syndrome in fragile X carrier males. Mov Disord 2002;17:744-745.
26. Feng Y, Zhang F, Lokey LK, et al. Translational suppression by trinucleotide repeat expansion at FMR1. Science 1995;268:731-734.
27. Primerano B, Tassone F, Hagerman RJ, et al. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 2002;8:1482-1488.
28. Tapscott SJ, Thornton CA. Reconstructing myotonic dystrophy. Science 2001;293:816-817.
29. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by CCTG expansion in intron of ZNF9. Science 2001;293:864-867.
30. Mankodi A, Logigian E, Callahan L, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000;289:1769-1772.
31. Savkur RS, Phillips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nature Genet 2001;29:40-47.